Establishment of radiotherapy- and chemotherapy-resistant medulloblastoma cell lines.

Recurrent medulloblastoma (MB) is nearly universally fatal, and surgery at the time of recurrence is associated with significant morbidity and discomfort1. Presently, novel agents are tested in children with recurrent MB based on the unsubstantiated assumption that a heavenly treated MB tumour at recurrence is highly similar to the tumour at diagnosis. However, a recent genomic study2 demonstrated that MB presents a striking evolutionary plasticity over time showing that only 11.8% of genetic alterations identified at diagnosis are also present in the recurrent tumour. This demonstrates a substantial genetic divergence at recurrence highlighting the need of better cellular systems to model the recurrent disease.

Grant Award – Kidscan Placement Student (2017-2018)
Funding Award – £2,000
Funding Awarded To – Dr Gianpiero Di Leva
Research Location – University of Salford
Lead Researcher – Dr Gianpiero Di Leva